CUSIP
No. 492515101
|
1
|
Name
of Reporting Person: Michael
S. Weiss
I.R.S.
Identification No. of Above Person (Entities Only):
|
||
2
|
Check
the Appropriate Box if a Member of a Group
(a)
o
(b)
o
|
||
3
|
SEC
Use Only
|
||
4
|
Source
of Funds
OO
|
||
5
|
Check
box if disclosure of legal proceedings is required pursuant to items
2(d)
or 2(e) o
|
||
6
|
Citizenship
or Place of Organization
United
States
|
||
NUMBER
OF
|
7
|
Sole
Voting Power:
5,213,635
|
|
SHARES
BENEFICIALLY
OWNED
BY
|
8
|
Shared
Voting Power: -
0 -
|
|
EACH
REPORTING
PERSON
|
9
|
Sole
Dispositive Power:
5,213,635
|
|
WITH
|
10
|
Shared
Dispositive Power: -
0 -
|
|
11
|
Aggregate
Amount Beneficially Owned by Each Reporting Person: 5,213,635
|
||
12
|
Check
Box if the Aggregate Amount in Row (9) Excludes Certain Shares o
|
||
13
|
Percent
of Class Represented by Amount in Row (9): 10.7%
|
||
14
|
Type
of Reporting Person:
IN
|
(a) |
The
Reporting Person filing this statement is Michael S. Weiss, a natural
person.
|
(b) |
The
address of Mr. Weiss’s principal business office is Keryx
Biopharmaceuticals, Inc., 750 Lexington Avenue, New York, New York
10022.
|
(c) |
Mr.
Weiss is the Chairman and Chief Executive Officer of Keryx.
|
(d) |
Mr.
Weiss has not, during the past five years, been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors).
|
(e) |
Mr.
Weiss has not, during the past five years, been party to a civil
proceeding of a judicial or administrative body of competent jurisdiction
and as a result of such proceeding, was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting
or
mandating activities subject to, federal or state securities laws
or
finding any violation with respect to such laws.
|
(f) |
Mr.
Weiss is a United States citizen.
|
(a) |
Mr.
Weiss may be deemed to be the beneficial owner of 5,213,635 shares
of
Common Stock. Such shares constitute approximately 10.7% of the issued
and
outstanding shares of Common Stock. As of February 8, 2008, there
were
43,706,153 shares of Common Stock outstanding. Included in Mr. Weiss’
percentage of beneficial ownership are shares underlying options
beneficially owned by Mr. Weiss that will vest within 60 days of
February
8, 2008. Options or warrants held by other stockholders that are
not
attributed to Mr. Weiss were disregarded in this calculation. Beneficial
ownership is determined in accordance with the rules of the Securities
and
Exchange Commission and includes voting or investment power with
respect
to the shares of Common Stock.
|
KERYX BIOPHARMACEUTICALS, INC. | ||
|
|
|
Date: February 8, 2008 | By: /s/ Michael S. Weiss | |
Name: Michael S. Weiss |
||
Title: Chairman
and Chief Executive Officer
|